developing custom, process-specific antibodies, or in running orthogonal methods for antibody and impurity characterization. Protein, technologies has established expertise in bioprocess development, through its Gyrolab platforms and Gyrolab ready-to-use kits for CHO-HCP, Protein, a impurity analyses, and IgG titer determinations. Developed to support assay development and validation for detection of anti-drug antibodies. Gyros Protein Technologies, enables peptide synthesis and bioanalytical solutions that help scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications. . These solutions and our chemistries deliver uncompromising purity, flexibility, and quality for discovery and pre-clinical studies of simple to complex multifunctional peptides. Gyros Protein Technologies has over 100 employees across the USA and Europe, and has development and manufacturing facilities in Uppsala, Sweden and Tucson, AZ, and a commercial site in Warren,. Due to the severity of the side effects in patients, regulatory agencies require pharmaceutical companies to perform immunogenicity studies as part of their biotherapeutic development programs. Gyrolab ADA solution provides a nanoliter-scale method for automated acid pre-treatment all in a Gyrolab Mixing CD with 96 microstructures or this flexible solution can be also used without christian lundell paf acid dissociation. Proprietary high performance nanoliter-scale immunoassay platforms, GyrolabxP workstation and Gyrolab xPlore, are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as immunogenicity, and quantitating bioprocess-related impurities. Protein, technologies with its proprietary reagents for host cell protein analysis, enabling the development of new Gyrolab immunoassay kits and applications to further support customers working in biotherapeutics development and manufacturing.
HomePeptide Synthesis BioanalysisGyros Protein Technologies Contact Gyros Protein Technologies Gyros Protein Technologies Appoints Peter Luk as Vice
Gyrolab users carrying out impurity analysis will now also benefit from the products and expertise provided by Cygnus Technologies. Uppsala, Sweden southport,.C.- business wire )-, gyros. Advertisement, organisation Details, gyros Protein Technologies is a leading provider of sample preparation, synthesis and bioanalytical tools for biotherapeutics discovery, development and bioprocessing. Uppsala, Sweden, June 29th, 2017 : Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, today announced it has launched a new version of its anti-drug antibody (ADA) solution for the immunogenicity market.
In patients, the resulting anti-drug antibodies can also cause allergic reactions, anaphylactic shock, or autoimmunity. Those same customers can also access custom antibody services along with state-of-the-art orthogonal analytical methods developed at Cygnus Technologies. Jasmine Gruia-Gray, VP Marketing, Gyros Protein Technologies, said: Biotherapeutic pharmacokinetics and drug efficacy can be impacted by the adverse immune responses to these drugs. Current majority shareholders of both Gyros AB and Protein Technologies, Inc., which are the AP6 and Ampersand Capital Partners respectively, become the major shareholders in Gyros Protein Technologies. The Gyrolab ADA protocol and dedicated analysis software designed for 21 CFR Part 11 compliance, streamline workflows from assay development through to screening and confirmation.
Gyros Protein Technologies introduces new ADA solution for
Apoteket uppsala öppettider påsk, Förenade care uppsala,